A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Co. Ltd. has described histone-lysine N-methyltransferase EZH1 and/or EZH2 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, metabolic diseases, and genetic, ...

Reflecting on my career as a physician-scientist, I’m reminded of guiding reasons why this path has aligned my interests and strengths. In my practice, I balance caring for bladder and kidney cancer ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based ...

EZH2 expression is required in the bone marrow for progression of pro-B cells into pre-B cells and immature B cells, because genetic inactivation of EZH2 leads to an accumulation of cells at the pro–B ...

Strengths: The authors investigate the role of Ezh2 in granule neuronal differentiation during cerebellar development and medulloblastoma (MB) progression, integrating multi-omics for a comprehensive ...

Ezh2 emerges as a powerful restraint upon post-mitotic differentiation during normal GNP development and combination of Ezh2 inhibition with cell cycle exit leads to MB cell differentiation.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies.

An innovative class of anticancer agents known as EZH2 inhibitors has shown promise in significantly boosting the effectiveness of certain cancer immunotherapies, according to a preclinical ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Epigenetics involves a series of biological processes that regulate chromatin-mediated DNA templates. 2 Cancer is a ...

EZH2 is frequently overexpressed in a variety of cancers, including head and neck, breast, prostate, bladder, colorectal, lung, pancreatic, melanoma, and lymphoma. Mutations in the EZH2 gene are also ...